CDKis, e.g., palbociclib, ribociclib, and abemaciclib, inhibit the cell cycle progression of cancer cells in patients with advanced or metastatic hormone receptor (HR)—positive and human epidermal growth factor receptor 2 (EGF-R)—negative cancer [3]. This evidence concerns the gene ERBB2 and cancer.